Sonnet BioTherapeutics Shares Are Trading Higher After the Company's Phase 1b/2a Clinical Trial of SON-080 Was Cleared to Proceed to Phase 2 After Review by an Independent DSMB
Sonnet BioTherapeutics股价走高,此前该公司的 SON-080 1b/2a期临床试验经独立DSMB审查后获准进入第二阶段
Sonnet BioTherapeutics Shares Are Trading Higher After the Company's Phase 1b/2a Clinical Trial of SON-080 Was Cleared to Proceed to Phase 2 After Review by an Independent DSMB
Sonnet BioTherapeutics股价走高,此前该公司的 SON-080 1b/2a期临床试验经独立DSMB审查后获准进入第二阶段
使用浏览器的分享功能,分享给你的好友吧